These are clinical trials registered on the ClinicalTrial.gov website:
1. Quality of Life Study for Sickle Cell Patients Treated With Jobelyn (Sorghum Bicolor Extract)
ClinicalTrials.gov Identifier:
NCT01704794
The purpose of this study is to determine the antioxidant effect of prolonged use of sorghum bicolor (jobelyn) to increase the level of plasma superoxide dismutase and glutathione reductase in patients with sickle cell disease and to determine if there is any improvement in the quality of life of the patients.
2. The Efficacy of Jobelyn (Sorghum Bicolor Extract)in the Treatment of Sickle Cell Anemia -
ClinicalTrials.gov Identifier:
NCT01703104
The primary objective is to determine if there is a significant increase in the haematocrit value of patients on Jobelyn and standard therapy compared to those on standard therapy alone.
3. The Safety and Effectiveness of Jobelyn in Pre-operative Management of Anaemia in Gynaecological Patients
ClinicalTrials.gov Identifier:
NCT01670955
PROTOCOL FOR THE STUDY OF THE SAFETY AND EFFICACY OF JOBELYN, IN THE PREOPERATIVE MANAGEMENT OF ANAEMIA IN GYNAECOLOGICAL PATIENTS
4.The Safety and Efficacy of Jobelyn in the Treatment of Breast Cancer Patients
ClinicalTrials.gov Identifier:
NCT01936064
To determine the effective functionality/potency of Jobelyn as an immunologic and haematologic booster in Breast cancer patients (start-off), thus improving the outlook and the quality of life of such patients generally
5. Efficacy of Jobelyn™ Consumption on Hemoglobin Levels in a Borderline Anemic Population
ClinicalTrials.gov Identifier:
NCT01828060
The purpose of this study is to evaluate the timing and magnitude of improvements to red blood cell health associated with consumption of Jobelyn™.
6. Antipsychotic Effects of Sorghum Bicolor (JOBELYN) in the Treatment of Schizophrenia
ClinicalTrials.gov ID: NCT02240173
Antipsychotic Effects of Sorghum Bicolor (JOBELYN) in the Treatment of Schizophrenia
1. Quality of Life Study for Sickle Cell Patients Treated With Jobelyn (Sorghum Bicolor Extract)
ClinicalTrials.gov Identifier:
NCT01704794
The purpose of this study is to determine the antioxidant effect of prolonged use of sorghum bicolor (jobelyn) to increase the level of plasma superoxide dismutase and glutathione reductase in patients with sickle cell disease and to determine if there is any improvement in the quality of life of the patients.
2. The Efficacy of Jobelyn (Sorghum Bicolor Extract)in the Treatment of Sickle Cell Anemia -
ClinicalTrials.gov Identifier:
NCT01703104
The primary objective is to determine if there is a significant increase in the haematocrit value of patients on Jobelyn and standard therapy compared to those on standard therapy alone.
3. The Safety and Effectiveness of Jobelyn in Pre-operative Management of Anaemia in Gynaecological Patients
ClinicalTrials.gov Identifier:
NCT01670955
PROTOCOL FOR THE STUDY OF THE SAFETY AND EFFICACY OF JOBELYN, IN THE PREOPERATIVE MANAGEMENT OF ANAEMIA IN GYNAECOLOGICAL PATIENTS
4.The Safety and Efficacy of Jobelyn in the Treatment of Breast Cancer Patients
ClinicalTrials.gov Identifier:
NCT01936064
To determine the effective functionality/potency of Jobelyn as an immunologic and haematologic booster in Breast cancer patients (start-off), thus improving the outlook and the quality of life of such patients generally
5. Efficacy of Jobelyn™ Consumption on Hemoglobin Levels in a Borderline Anemic Population
ClinicalTrials.gov Identifier:
NCT01828060
The purpose of this study is to evaluate the timing and magnitude of improvements to red blood cell health associated with consumption of Jobelyn™.
6. Antipsychotic Effects of Sorghum Bicolor (JOBELYN) in the Treatment of Schizophrenia
ClinicalTrials.gov ID: NCT02240173
Antipsychotic Effects of Sorghum Bicolor (JOBELYN) in the Treatment of Schizophrenia
